[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,712,201
  • Shares Outstanding, K 119,828
  • Annual Sales, $ 0 K
  • Annual Income, $ -377,940 K
  • EBIT $ -410 M
  • EBITDA $ -411 M
  • 60-Month Beta 0.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 20.88

Options Overview Details

View History
  • Implied Volatility 65.10% (-1.47%)
  • Historical Volatility 44.02%
  • IV Percentile 51%
  • IV Rank 14.52%
  • IV High 152.07% on 09/22/25
  • IV Low 50.33% on 01/22/26
  • Expected Move (DTE 27) 2.55 (5.35%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 22
  • Volume Avg (30-Day) 620
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 17,379
  • Open Int (30-Day) 11,829
  • Expected Range 45.12 to 50.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 6
  • High Estimate $-0.79
  • Low Estimate $-0.89
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.28 +0.84%
on 07/22/26
58.49 -18.50%
on 07/10/26
-4.66 (-8.91%)
since 06/24/26
3-Month
43.23 +10.27%
on 06/11/26
58.49 -18.50%
on 07/10/26
+1.19 (+2.56%)
since 04/24/26
52-Week
27.07 +76.10%
on 11/07/25
58.49 -18.50%
on 07/10/26
+8.56 (+21.89%)
since 07/24/25

Most Recent Stories

More News
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab...

SRRK : 47.67 (-3.66%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 118,586 shares of its common stock to eleven newly hired employees,...

SRRK : 47.67 (-3.66%)
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open. The Company will host...

SRRK : 47.67 (-3.66%)
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 47.67 (-3.66%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees,...

SRRK : 47.67 (-3.66%)
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 47.67 (-3.66%)
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 47.67 (-3.66%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees,...

SRRK : 47.67 (-3.66%)
Scholar Rock Q1 Earnings Call Highlights

Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for...

SRRK : 47.67 (-3.66%)
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action...

SRRK : 47.67 (-3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 51.64
2nd Resistance Point 50.80
1st Resistance Point 49.23
Last Price 47.67
1st Support Level 46.82
2nd Support Level 45.98
3rd Support Level 44.41

See More

52-Week High 58.49
Last Price 47.67
Fibonacci 61.8% 46.49
Fibonacci 50% 42.78
Fibonacci 38.2% 39.07
52-Week Low 27.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.